Clinical Trials

A clinical trial evaluating Astragaloside II, sponsored by the Poznan University of Medical Sciences as an academic institution, is currently actively recruiting participants. The research focuses on acute coronary syndrome and cardiac rehabilitation, evaluating overall patient health during post-event recovery. Designated as Phase Not Applicable, this study reflects ongoing clinical evaluation within cardiovascular care.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03935438 Recruiting
Cardiac Rehabilitation|Acute Coronary Syndrome
Poznan University of Medical Sciences
2019-04-12 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Astragaloside II product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Astragaloside II modulates intracellular signaling networks and immune response pathways, downstream of its molecular interactions, to regulate T cell activation and promote cellular differentiation and tissue wound repair. These biological effects facilitate tissue regeneration and cellular restoration, providing a rationale for its investigation in patients undergoing cardiac rehabilitation following acute coronary syndrome.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.